Background {#Sec1}
==========

The human papillomavirus (HPV) is an important preventable cause of sexually-transmitted disease and squamous cell carcinomas. HPV types 16 and 18 have been implicated in cervical, anal, vaginal, and vulvar cancers, while types 6 and 11 cause anogenital warts. Between 2003 and 2004, the overall HPV prevalence was 26.8 % \[[@CR1]\]. Moreover, the prevalence of HPV infections statistically significantly increased with each year of age from 14 to 24 (*p* \< 0.001) \[[@CR1]\]. The National Cancer Institute independently developed the HPV vaccine, which was subsequently sold to Merek & Co and GlaxoSmithKline for randomized controlled trials (RCTs). The HPV vaccine studies were subsequently marketed as a novel intervention to curtail the infection's oncologic aptitude. Years of clinical trials by the pharmaceutical companies have materialized into two Food and Drug Administration (FDA)-approved HPV vaccine. First, Gardasil or Silgard (Merck & Co) is a human recombinant papillomavirus vaccine- quadrivalent types 6,11,16,18. Second, Cervarix (GlaxoSmithKline) is a bivalent human papillomavirus vaccine- types 16, 18. While the efficacy of both vaccines has been verified in randomized control studies (RCT) \[[@CR2]--[@CR4]\], the safety of these prophylactic interventions has been strongly contested in the outpatient settings.

Methods {#Sec2}
=======

The literature review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR5]\]. A search of PubMed articles for "human papillomavirus vaccine" was used to identify all-type HPV clinical studies prior to October 2014. A refined search of clinical trials, multicenter studies, and randomized studies were screened for only randomized controlled trials comparing HPV vaccine to controls (saline placebo or aluminum derivatives). With a compilation of previously published RCTs, we compared adverse effects from the HPV vaccine versus control injection. The primary endpoint was to determine the safety of the HPV vaccine. The literature review outlined in Table [1](#Tab1){ref-type="table"} includes the primary author, publication year, number study participants, description of the study population, type of adverse events, number of vaccinated and unvaccinated participants for whom adverse events (AE) are reported, and *P* value comparison between the two cohorts.Fig. 1PRISMA Flow Diagram for publication selection Table 1Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trialsAuthor, YearStudy populationInclusion criteriaAdverse eventsVaccine group (%)Control group (%)*P*Harper et al. 2004 \[[@CR6]\]*N* = 1113 women from 32 study sites in North America and Brazil.15--25 years\
≤6 lifetime sexual partners\
No abnormal Pap test\
No external condylomata\
HPV 16/18 seronegative7-day period*N* = 531 Gardasil*N* = 538 Al(OH)~3~Injection-site symptoms\
Pain\
Swelling\
Redness\
General symptoms\
Fatigue\
Gastrointestinal\
Headache\
Itching\
Rash\
Fever499 (93.97)\
496 (93.41)\
182 (34.27)\
189 (35.59)\
458 (56.25)\
308 (58.00)\
178 (33.52)\
331 (62.34)\
130 (24.48)\
60 (11.30)\
88 (16.57)472 (87.73)\
469 (87.17)\
113 (21.00)\
131 (24.35)\
462 (85.87)\
289 (53.72)\
172 (31.97)\
329 (61.15)\
109 (20.26)\
54 (10.04)\
73 (13.57)**\<0.001**\
**\<0.001**\
**\<0.001**\
**\<0.001**\
0.860\
0.175\
0.602\
0.706\
0.106\
0.552\
0.172Entire study period (0--27 months)Vaccine-related serious adverse event\
Discontinuation for non-serious adverse event\
Discontinuation for serious adverse event^d^0\
0\
1 (0.19)0\
3 (0.56)\
01.000\
0.249\
0.497Villa et al. 2005 \[[@CR7]\]*N* = 277 women from Brazil, Europe, and USA16--23 years\
Non-pregnant\
No abnormal Pap smears\
≤4 lifetime sex partners*N* = 272 Gardasil*N* = 274 AAHSVaccine-associated adverse events\
Injection-site\
Systemic\
Vaccine-related serious adverse events\
Discontinued vaccination due to hypoaesthesia243 (89.34)\
234 (86.03)\
104 (38.24)\
0\
0225 (82.12)\
212 (77.37)\
90 (32.85)\
0\
1 (0.36)**0.016**\
**0.009**\
0.188\
1.000\
0.319Reisinger et al. 2007 \[[@CR16]\]*N* = 1781 children from 47 sites in 10 countries in North America, Latin America, Europe, and Asia, enrolled from December 2002 to September 20049--15 years old\
Sexually naïve\
Intact uterus\
No gross purulent cervicitis\
No genital warts\
No abnormal Pap smear\
No cervical intraepithelial neoplasia\
≤4 lifetime sex partners\
Non-pregnant15-day period*N* = 1165 Gardasil*N* = 584 Saline≥1 adverse events\
Injection-site adverse events\
Erythema\
Pain\
Swelling\
Systemic adverse events\
Serious vaccine-related adverse events963 (82.66)\
877 (75.28)\
237 (20.34)\
853 (73.22)\
241 (20.68)\
541 (46.44)\
0392 (97.12)\
292 (50.00)\
77 (13.18)\
265 (45.38)\
45 (7.71)\
260 (44.52)\
0**\<0.001**\
**\<0.001**\
**\<0.001**\
**\<0.001**\
**\<0.001**\
0.448\
1.000*N* = 1157*N* = 579Fever1074 (92.83)541 (93.44)0.638Merck V501-013\
FUTURE I Study\
Garland et al. 2007 \[[@CR2]\]*N* = 5455 women at 62 study sites in 16 countries, enrolled from January 2002 to March 200316--24 year old\
Non-pregnant\
No history of genital warts\
No abnormal cervical cytology testing\
≤4 lifetime sex partners\
Effective contraception5-day period*N* = 2673 Gardasil*N* = 2672 AAHSInjection-site event\
Erythema\
Pain\
Pruritus\
Swelling2320 (86.79)\
659 (24.65)\
2281 (85.33)\
109 (4.70)\
694 (25.96)2068 (77.40)\
450 (16.84)\
2014 (75.37)\
80 (2.99)\
413 (15.46)**\<0.001**\
**\<0.001**\
**\<0.001**\
**\<0.001**\
**\<0.001**15-day periodInjection-related systemic event\
Pyrexia1161 (43.43)\
361 (13.51)1085 (40.61)\
272 (10.18)**0.036**\
**\<0.001**Entire study periodVaccine-related serious event^a^\
Discontinuation for vaccine-related event\
Death1 (0.03)\
0\
2 (0.07)0\
0\
2 (0.07)0.317\
1.000\
0.999Merck V501-015\
FUTURE II Study, 2007 \[[@CR3]\]*N* = 12,167 women in 13 countries, enrolled from June 2002 to March 200315--26 year old\
Non-pregnant\
No abnormal Papanicolaou smear\
≤4 lifetime sex partners\
Effective contraception15-day period*N* = 448 Gardasil*N* = 447 AAHS≥1 adverse eventInjection-site event\
Pain\
Systemic event378 (84.38)\
372 (83.04)\
275 (61.38)348 (77.85)\
339 (75.84)\
268 (59.96)**0.012**\
**0.008**\
0.662Entire study period*N* = 6019*N* = 6031Serious injection-related event^b^\
Discontinuation for serious injection-related event\
Death3 (0.05)\
0\
7 (0.12)2 (0.03)\
0\
5 (0.08)0.202\
1.000\
0.338Muñoz et al. 2009 \[[@CR8]\]*N* = 3819 women from 38 international sites in Colombia, France, Germany, Philippines, Spain, Thailand, and USA24--45 year old\
Non-pregnant\
Intact uterus\
No genital warts or cervical disease\
HIV seronegative15-day period*N* = 1889 Gardasil*N* = 1886 AAHSVaccine-related adverse events\
Injection-site adverse events\
Systemic adverse events\
Serious vaccine-related adverse events1565 (82.84)\
1449 (76.71)\
745 (39.44)\
01389 (73.65)\
1212 (64.26)\
695 (36.85)\
0**\<0.001**\
**\<0.001**\
0.102\
1.000Bhatla et al. 2010 \[[@CR9]\]*N* = 330 women at four teaching/ tertiary care hospitals across India, enrolled from July 2006 to March 2007Non-pregnant\
No investigational products/ steroids\
Contraception or sexual abstinence7-day period*N* = 171 Cervarix*N* = 174 Al(OH)~3~Pain, all-type\
Grade 3 Pain\
Redness, any size\
\>50 mm\
Swelling, any size\
\>50 mm\
Grade 3 solicited general symptoms\
Medically significant adverse event\
Serious adverse events\
Acute pancreatitis\
Lymph node tuberculosis\
Bronchogenic cyst\
Cataract\
Miscarriage\
Pneumothorax\
Death137 (80.12)\
35 (20.47)\
56 (32.75)\
1 (0.58)\
69 (40.35)\
5 (2.92)\
11 (6.43)\
13 (7.60)\
2 (1.717)\
1 (0.58)\
1 (0.58)\
0\
0\
0\
0\
0105 (60.34)\
7 (4.02)\
24 (13.79)\
1 (0.57)\
35 (20.11)\
3 (1.72)\
10 (5.75)\
24 (13.79)\
4 (2.30)\
0\
0\
1 (0.57)\
1 (0.57)\
1 (0.57)\
1 (0.57)\
0**\<0.001**\
**\<0.001**\
**\<0.001**\
0.990\
**\<0.001**\
0.459\
0.790\
0.063\
0.422\
0.312\
0312\
0.321\
0.321\
0.321\
0.321\
1.00Ngan et al. 2010 \[[@CR10]\]*N* = 300 women at a single center in Hong Kong18--35 year old\
No chronic disease\
Non-pregnant/ breastfeedingEntire study period*N* = 145 Cervarix*N* = 145 Al(OH)~3~Abdominal pain, IBS, dizziness, headache\
Pelvic inflammatory disease\
Medically significant conditions\
New onset chronic disease3 (2.07)\
0\
42 (2.90)\
7 (4.83)0\
1 (0.69)\
24 (16.55)\
5 (3.44)0.082\
0.316\
**0.012**\
0.555Levin et al. 2010 \[[@CR11]\]*N* = 126 children HIV-seropositive children7--12 years old\
HIV with CD4 ≥ 15 %\
≥3 months HAART if CD4 \< 25 %14-day period*N* = 96 Gardasil*N* = 30 Saline PlaceboAdverse events\
Ear, eye, respiratory symptom\
Injection-site reactions\
Laboratory abnormality\
Systemic reactions\
Other35 (36.46)\
1 (1.04)\
21 (21.89)\
3 (3.13)\
2 (2.08)\
1 (1.04)15 (50.00)\
1 (3.33)\
3 (10.00)\
1 (3.33)\
1 (3.33)\
1 (3.33)0.186\
0.381\
0.148\
0.955\
0.695\
0.381V501-20\
Giuliano et al. 2011 \[[@CR12], [@CR39]\]*N* = 4065 males from 71 sites in 18 countries16--26 years old\
1--5 male or female sexual partners\
No anogenital lesions15-day period*N* = 1945 Gardasil*N* = 1950 AAHSVaccine-related events\
Injection-site\
Systemic\
Vaccine-related serious events\
Death\
Discontinuation for vaccine-related adverse event^e^1242 (63.86)\
1169 (60.10)\
274 (14.09)\
0\
0\
2 (0.10)1134 (58.15)\
1046 (53.64)\
284 (14.56)\
0\
0\
3 (0.15)**\<0.001**\
**\<0.001**\
0.67\
1.000\
1.000\
0.657Entire study periodVaccine-related events\
Injection-site\
Systematic\
Vaccine-related serious events\
Death\
Discontinuation for vaccine-related adverse event^e^1242 (63.86)\
1169 (60.10)\
274 (14.09)\
0\
3\
2 (0.10)1134 (58.15)\
1046 (53.64)\
284 (14.56)\
0\
10\
3 (0.15)**\<0.001**\
**\<0.001**\
0.67\
1.00\
0.052\
0.657Sow et al. 2013 \[[@CR13]\]*N* = 676 women in 2 centers in sub-Saharan Africa (Senegal and Tanzania) from October 2007 to July 201010--25 years old\
HIV seronegative\
Not pregnant\
≤6 lifetime sexual partners0--12 months\**N* = 450 Cervarix*N* = 226 Al(OH)~3~Grade 3 injection-site pain\
Serious adverse event^c^\
Medically significant condition\
New onset chronic disease\
New onset autoimmune disease\
Deaths\
Premature births- infant death2 (0.44)\
17 (3.78)\
312 (69.33)\
11 (2.44)\
2 (0.44)\
0\
1 (0.22)0\
14 (6.19)\
170 (75.22)\
11 (4.87)\
2 (0.88)\
0\
1 (0.44)0.316\
0.156\
0.110\
0.094\
0.481\
1.000\
0.619Yoshikawa et al. 2013 \[[@CR14]\]*N* = 1030 Japanese women, multicenter18--26 years old\
Not pregnant\
No previous abnormal Pap smears\
≤4 males sex partners\
Effective contraceptionDays 1--15*N* = 480 Gardasil*N* = 468 AAHSAll-type adverse event\
Injection-site adverse event\
Systemic adverse event\
Serious adverse event\
Discontinuation for vaccine-related adverse event^f^\
Death417 (86.88)\
408 (85.00)\
66 (13.75)\
0\
1 (0.21)\
0347 (74.15)\
338 (72.22)\
53 (11.32)\
0\
0\
0**\<0.001**\
**\<0.001**\
0.260\
1.000\
1.000Denny et al. 2013 \[[@CR15]\]*N* = 150 women at a single center in Khayelitsha, Cape Town, Republic of South Africa.18--25 years old\
≤6 lifetime sexual partners\
Non-pregnant\
Intact cervix30-day period*N* = HIV 61 (+)/30 (-) Cervarix*N* = 59 HIV(+) Al(OH)~3~Unsolicited adverse event\
Headache\
Upper respiratory tract infection\
Lobar Pneumonia (Grade 3)\
Bacterial Pneumonia (Grade 3)53 (86.89)/ 26 (86.67)\
12 (19.67)/ 4 (13.33)\
10 (16.39)/ 7 (23.33)\
1 (1.64)/ 0 (0.00)\
0/ 046 (77.97)\
14 (23.73)\
10 (16.95)\
0\
1 (1.69)0.199\
0.590\
0.935/0.390\
0.323/1.000\
0.311/0.473Up to 7 monthsMedically significant adverse event18 (29.51)/5 (16.67)21 (35.59)0.477/0.0637--12 months*N* = HIV54 (+)/ 24 (-)*N* = 52 HIV(+)Medically significant adverse event\
Discontinuation for vaccine-related adverse event6 (11.11)/ 2 (8.33)\
0/ 05 (9.62)\
00.801/0.857\
1.000Statistically significant values are in bold\*Number of adverse events expressed as a function of the number of doses, rather than the number of patients, were excluded. These adverse events included malaria, headache, dysmenorrhea, abdominal pain, vertigo, cough, nasopharyngitisAmorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant; aluminum hydroxide \[Al(OH)~3~\]^a^Bronchospasm 1 day after the third dose^b^Serious adverse events in the vaccine group were gastroenteritis, headache, hypertension, injection-site pain, and decrease in joint movement at the injection site^c^Serious adverse events in both the vaccinated and control groups were likely due to malaria infection, unrelated to the vaccine^d^Elective discontinuation in the vaccine group was due to spontaneous abortion, unrelated to the vaccine^e^Elective discontinuation in the vaccine group was due to vaccine-related malaise and headache^f^Elective discontinuation in the vaccine group was due to vaccine-related pyrexia

Both solicited and unsolicited adverse events were included in the review. AE were determined by the article investigator as possibly, probably, or definitely related to the vaccine. AE were categorized according to the discrete time intervals during which the unintended outcome occurred. HPV vaccine was typically administered in a 3-dose schedule. The number of adverse events was expressed as a proportion of subjects, rather than the proportion of doses.

Inclusion/ Exclusion criteria {#Sec3}
-----------------------------

Only randomized controlled trials were included in the present article. Vaccination groups were limited to the two FDA-approved HPV vaccinations: (1) quadrivalent HPV-6,11,16,18 L1 virus-like particle (VLP) vaccine; (2) HPV-16,18 Adjuvant System (AS) 04 vaccine. Vaccines are composed of either quadrivalent or bivalent antigens plus either an amorphous aluminum hydroxyphosphate sulfate (AAHS) adjuvant or aluminum hydroxide \[Al(OH)~3~\]. Control cohorts were limited to solutions containing either (A) saline placebo; or (B) identical components to those in the vaccine, with the exception of the HPV antigens. Twelve articles included AAHS or Al(OH)~3~ placebo \[[@CR2], [@CR3], [@CR6]--[@CR15]\]; however, Reisinger et al. utilized a saline placebo \[[@CR16]\]. RCTs with hepatitis A and/or hepatitis B vaccine controls were excluded \[[@CR17]--[@CR29]\]. Control groups without injections were also removed from the literature review insomuch as the study design would interfere with the blinded schema and become susceptible to a reporting bias/ information bias \[[@CR30]\]. Randomized controlled trials without mention of adverse events and/or non-clinical RCTs were excluded from the literature review. Repeat studies, ad hoc subgroup analysis, and pooled analyses were similarly excluded \[[@CR4], [@CR31]--[@CR38]\]. Lastly, AE expressed as a percentage of doses, rather than a percentage of study participants, were not included in Table [1](#Tab1){ref-type="table"} \[[@CR13]\].

Statistical analysis {#Sec4}
--------------------

Demographic information was described using summary statistics. The percent of subjects who experienced an AE in the vaccine group were compared to the placebo counterparts with Chi-squared (χ^2^) tests. Stata (version 12.0, College Station, TX, USA) and GraphPad Software were used for statistical interpretations of the raw data. Statistical significance was set a *p* ≤ 0.05.

Results {#Sec5}
=======

The PRISMA flow diagram detailing the selection process is presented in Fig. [1](#Fig1){ref-type="fig"}. The most common reason for exclusion was non-randomized, clinical-controlled trials (*n* = 230). Of the 86 RCTs, the most prevalent exclusion criteria was non-clinical studies/ studies without mention of AE (*n* = 29), followed by HPV RCTs with vaccines other than the quadrivalent HPV-6,11,16,18 L1 VLP or bivalent HPV-16,18 AS04. Following PRISMA guidelines, the literature review rendered 13 publications that met the aforementioned inclusion/ exclusion criteria \[[@CR2], [@CR3], [@CR6]--[@CR16], [@CR39]\]. Most clinical studies were sufficiently powered to detect a statistically significant difference between the vaccination and control cohorts, with the smallest study population of 150 women in the RCT by Denny et al. \[[@CR15]\].

In the present literature review, the study population consisted of 31,289 subjects, 98.87 % of whom (*n* = 30,934) had follow-up data available for documentation of adverse events. Gender was limited to females in 10 studies \[[@CR2], [@CR3], [@CR6]--[@CR10], [@CR13]--[@CR15]\] and males in 1 study \[[@CR12]\]. Two studies included both males and females \[[@CR11], [@CR16]\]. Ages ranged from 9 to 45 years. The sample populations were derived from multi-national institutions, with the exception of a Chinese trial by Ngan et al. and a Japanese trial by Yoshikawa et al. \[[@CR10], [@CR14]\]. Similarly, all trials were multi-center studies, with the exception of a single-institutional RCT in Hong Kong \[[@CR10]\]. The most common study inclusion criteria were ≤4--6 lifetime sexual partners, no abnormal Papanicolaou smears, non-pregnant, and no cervical infections/ anogenital warts. Women were encouraged to utilize effective contraception. Two studies specifically focused on Human Immunodeficiency Virus (HIV)-seropositive participants \[[@CR11], [@CR15]\].

Of the 11,189 individuals in 7 publications reporting cumulative, all-type adverse events\[[@CR7], [@CR8], [@CR11], [@CR12], [@CR14]--[@CR16]\], the AE incidence of 76.52 % (*n* = 4544) in the vaccinated group was statistically significantly higher than 67.57 % (*n* = 3548) in the placebo group (*p* \< 0.001). The most common AE were injection-site reactions. In fact, of the 18,348 participants in 9 reporting articles \[[@CR2], [@CR3], [@CR6]--[@CR8], [@CR11], [@CR12], [@CR14], [@CR16]\], the 77.43 % of vaccinated subjects (*n* = 7355) who experienced all-type injection-site reactions was statistically significantly higher than the 67.70 % of control subjects (*n* = 5991) (*p* \< 0.001). The most common injection-site reactions were pain, induration, and erythema. On the other hand, systemic symptoms did not statistically significantly differ between the vaccination cohort (35.28 %, *n* = 3351) and the placebo cohort (36.14 %, *n* = 3198) (*p* = 0.223). The most common systemic symptoms included fatigue, headache, and fever. Ten articles (*n* = 30,398) reported serious adverse events \[[@CR2], [@CR3], [@CR6]--[@CR9], [@CR12]--[@CR14], [@CR16]\]. The incidence of 0.15 % (*n* = 23) in the vaccination division did not statistically significantly differ from 0.14 % (*n* = 20) in the control counterparts (*p* = 0.774). Of the 23 subjects experiencing serious AE, 17 (73.91 %) were attributable to malaria infection, unrelated to the vaccine, in the sub-Saharan Africa study by Sow et al. \[[@CR13]\]. Serious AE in the remaining 6 vaccinated subjects included bronchospasm, acute pancreatitis, lymph node tuberculosis, gastroenteritis, headache, and hypertension. Only 4 patients (0.03 %) in the vaccine unit \[[@CR6], [@CR12]\] and 7 patients (0.06 %) in the control unit \[[@CR6], [@CR7], [@CR12], [@CR14]\] discontinued the study due to adverse events (*p* = 0.367). Of the four elective terminations in the vaccine group, three men cited vaccine-related malaise, headache, and pyrexia in the publications by Giuliano et al. \[[@CR12], [@CR39]\] and Yoshikawa et al. \[[@CR14]\], whereas one woman experienced a spontaneous abortion in the publication by Harper et al. \[[@CR6]\], thought to be unrelated to the vaccine. Twelve and seventeen individuals died in the vaccine and control groups, respectively. Causes of death in the vaccine cohort included pneumonia and sepsis, overdose of an illicit drug, motor vehicle accident (6 persons), pulmonary embolism, infective thrombosis, homicide, and suicide, none of which were linked with the vaccine \[[@CR2], [@CR3], [@CR12]\].

Ngan et al. and Sow et al. reported new-onset chronic disease/ autoimmune disease following injection with drug vs control \[[@CR10], [@CR13]\]. Of the 966 enrollees in the two studies, the rate of 3.36 % in the vaccine randomization did not statistically significantly differ from 4.85 % in the control randomization (*p* = 0.246). Lastly, while effective contraception and non-pregnancy represented key selection criteria for most RCTs in the present literature review, pregnancy was reported in the follow up period. Birth complications included one spontaneous abortion, nine elective abortions, and one death of a premature infant in the vaccination cohort in comparison to one spontaneous abortion, one miscarriage, one ectopic pregnancy, three elective abortions, and one death of a premature infant in the control cohort. None of these experiences were liked with the injections. The pregnancy/ perinatal outcomes from the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I (Merck V501-013), FUTURE II (Merck V501-015), Merck V501-016, and Merck V501-018 RCTs were combined in the Appendix in the FUTURE II study (Merck V501-016, 018 did not meet selection criteria in this literature review) \[[@CR38]\]. In brief, no statistically significant difference was observed between the vaccine group and control group.

Discussion {#Sec6}
==========

In 1796, an English physician, Edward Jenner, performed the first vaccination by inoculating an 8-year-old boy with pus from a cowpox lesion \[[@CR40]\]. Despite the growing safety concerns for his experimental design of a smallpox vaccine, Dr. Jenner published his conclusions in a landmark text in the annals of medicine: *Inquiry into the Causes and Effects of the Variolae Vaccine* \[[@CR41]\]. Since the development of Dr. Jenner's time-honored work, vaccine production over the ensuing centuries have ushered in a new era of preventive medicine; nevertheless, safety concerns for vaccination of children and young adults still remains the greatest barrier to these scientific advancements. A testament to this belief today, the most recent FDA-approved vaccines, Gardasil/Silgard and Cervarix, have met significant resistance owing to the fear of unknown side-effects. In this literature review, we compared adverse effects from the HPV vaccine versus control injection from a compilation of published randomized controlled trials. The primary endpoint of this study was to determine the safety of the HPV vaccine.

In the present literature review, the vaccine was well-tolerated without undue AE. All-type AE and injection-related AE were the only two parameters with a significantly higher rate in the HPV vaccinated subjects, whereas systemic events, serious AE, and death did not differ. The vaccine cohort (76.52 %) carried an approximately 10 % higher rate of all-type adverse events in comparison to the control cohort (67.57 %) (*p* \< 0.001). These results corroborate a sub-analysis by Moreira et al. \[[@CR39]\], who reviewed AE in the 4065 males enrolled in the HPV RCT, V501-20 published by Giuliano et al. \[[@CR12]\]. The 1945 males randomized to the Gardasil unit experienced a statistically significantly higher rate of all-type AE (63.86 %) versus AAHS adjuvants (58.15 %) (*p* \< 0.001). In fact of the 7 publications reporting all-type adverse events, 5 found a significant difference between the two cohorts \[[@CR7], [@CR8], [@CR12], [@CR14], [@CR16]\]. The remaining two articles reporting no difference were limited by a cohort size of less than 100 persons \[[@CR11], [@CR15]\]. The most common AE was injection-site reactions, such as pain, erythema, and induration. In the present literature review, all-type injection-site reactions were statistically significantly higher in the vaccine arm (77.43 %) than the control arm (67.70 %) (*p* \< 0.001). However, true injection-site, hypersensitivity reactions occur infrequently, according a retrospective review of 380,000 doses of Gardasil administered to 12--26 year-old females in Victoria and South Australia \[[@CR42]\]. In that study, only 35 females had suspected hypersensitivity reactions. Moreover, Kang et al. concluded that "only three of the 25 evaluated schoolgirls had probable hypersensitivity to the quadrivalent human papillomavirus vaccine \[[@CR42]\]." Several authors contend that the causes of the general injection-site reactions, and the hypersensitivity experiences specifically, are not completely attributable to the antigenic components of the vaccine, but rather due in part to the aluminum additives \[[@CR39], [@CR42]\]. In the RCT by Reisinger et al. (Table [1](#Tab1){ref-type="table"}), the placebo group was given saline injections, from which only half of participants experienced injection-site reactions \[[@CR16]\]. By comparison, the frequency of injection-site reactions averages at 68.95 % in control arms with Al(OH)~3~ or AAHS and 77.43 % in the vaccinated arm, per the set literature review. Such a gradient effect suggests that the aluminum products contribute to the reactogenicity of the vaccine \[[@CR39]\].

Systemic events did not differ in the vaccine division (35.28 %) versus the control division (36.14 %) (*p* = 0.223); furthermore, most reported symptoms were mild or moderate in intensity. Fatigue, headache, and pyrexia were most commonly documented throughout the follow up period. Delayed in onset, these experiences likely reflect the initial innate immunologic response followed by a sustained, adaptive response. Yoshikawa et al. did detect a statistically significant difference of all-type adverse events between the vaccine arm and control arm (*p* \< 0.001) (Table [1](#Tab1){ref-type="table"}) \[[@CR14]\]. The most common AE was injection-site adverse event, among which pain was the most frequent symptom. Systemic AE were the next most common event, although no statistically significant difference was detected between the vaccine and control cohorts (*p* = 0.260). Greater than 90 % of those systemic AEs were of "moderate intensity," without any specification.

Serious AE in the present study did not statistically significantly differ between the vaccine (0.15 %) and control (0.14 %) groups (*p* = 0.774) in the present literature review. Commensurate with our findings, Roumbout et al. reported no difference in serious AE in a systematic review of six HPV trials (Peto odds ratio 1.00; 95 % CI 0.87--1.14). Death between the two arms did not differ (Peto odds ratio 0.91; 95 % CI 0.39--2.14) \[[@CR43]\]. In the aforementioned review by Roumbout et al. as well as the present review, motor vehicle accidents were the most common cause of death. No mortalities were associated with the vaccine.

Conclusion {#Sec7}
==========

Following PRISMA guidelines, the literature review rendered 13 randomized controlled trials comparing HPV vaccine to control. Of the 11,189 individuals in 7 publications reporting cumulative, all-type adverse events, the vaccinated group was statistically significantly higher than the control group, although the most common AE were injection-site reactions. On the other hand, systemic symptoms did not statistically significantly differ. The pregnancy/ perinatal outcomes rendered no statistically significant difference between the vaccine group and control group. Thus, the vaccinations are safe preventative measures for both males and females.

\[Al(OH)~3~\]

:   Aluminum hydroxide

AAHS

:   Amorphous aluminum hydroxyphosphate sulfate

AE

:   Adverse events

AS

:   Adjuvant System

FDA

:   Food and Drug Administration

FUTURE

:   Females United to Unilaterally Reduce Endo/Ectocervical Disease

HIV

:   Human Immunodeficiency Virus
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:   Human papilloma virus
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:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

RCTs

:   Randomized controlled trials
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